External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases

This is an interventional treatment trial for Cancer focused on measuring tumors metastatic to brain, stage IV adenoid cystic carcinoma of the oral cavity, stage IV adrenocortical carcinoma, stage IV adult Burkitt lymphoma, stage IV adult diffuse large cell lymphoma, stage IV adult diffuse mixed cell lymphoma, stage IV adult diffuse small cleaved cell lymphoma, stage IV adult Hodgkin lymphoma, stage IV adult immunoblastic large cell lymphoma, stage IV adult lymphoblastic lymphoma, stage IV adult T-cell leukemia/lymphoma, stage IV anal cancer, stage IV basal cell carcinoma of the lip, stage IV bladder cancer, stage IV borderline ovarian surface epithelial-stromal tumor, stage IV breast cancer, stage IV childhood anaplastic large cell lymphoma, stage IV childhood Hodgkin lymphoma, stage IV childhood large cell lymphoma, stage IV childhood liver cancer, stage IV childhood lymphoblastic lymphoma, stage IV childhood small noncleaved cell lymphoma, stage IV chronic lymphocytic leukemia, stage IV colon cancer, stage IV cutaneous T-cell non-Hodgkin lymphoma, stage IV esophageal cancer, stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity, stage IV follicular thyroid cancer, stage IV gastric cancer, stage IV grade 1 follicular lymphoma, stage IV grade 2 follicular lymphoma, stage IV grade 3 follicular lymphoma, stage IV hypopharyngeal cancer, stage IV inverted papilloma of the paranasal sinus and nasal cavity, stage IV laryngeal cancer, stage IV lip and oral cavity cancer, stage IV lymphoepithelioma of the nasopharynx, stage IV lymphoepithelioma of the oropharynx, stage IV mantle cell lymphoma, stage IV marginal zone lymphoma, stage IV midline lethal granuloma of the paranasal sinus and nasal cavity, stage IV mucoepidermoid carcinoma of the oral cavity, stage IV mycosis fungoides/Sezary syndrome, stage IV nasopharyngeal cancer, stage IV non-small cell lung cancer, stage IV oropharyngeal cancer, stage IV ovarian epithelial cancer, stage IV pancreatic cancer, stage IV papillary thyroid cancer, stage IV paranasal sinus and nasal cavity cancer, stage IV penile cancer, stage IV prostate cancer, stage IV rectal cancer, stage IV renal cell cancer, stage IV salivary gland cancer, stage IV small lymphocytic lymphoma, stage IV squamous cell carcinoma of the hypopharynx, stage IV squamous cell carcinoma of the larynx, stage IV squamous cell carcinoma of the lip and oral cavity, stage IV squamous cell carcinoma of the nasopharynx, stage IV squamous cell carcinoma of the oropharynx, stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity, stage IV endometrial carcinoma, stage IV verrucous carcinoma of the larynx, stage IV verrucous carcinoma of the oral cavity, stage IVB vulvar cancer, stage IV Wilms tumor, stage IVB cervical cancer, stage IVB vaginal cancer, metastatic adult malignant fibrous histiocytoma of bone, metastatic childhood malignant fibrous histiocytoma of bone, metastatic gastrointestinal carcinoid tumor, metastatic parathyroid cancer, metastatic pheochromocytoma, metastatic squamous neck cancer with occult primary squamous cell carcinoma, metastatic squamous neck cancer with occult primary, metastatic transitional cell cancer of the renal pelvis and ureter, disseminated neuroblastoma, unspecified adult solid tumor, protocol specific, unspecified childhood solid tumor, protocol specific, tongue cancer Read More

DISEASE CHARACTERISTICS:

• Histologically confirmed metastatic cancer with brain metastases

  • Biopsy of brain metastases is not required

• All cancer types allowed, except for the following:

  • Prostatic adenocarcinoma
  • Sarcoma
  • Melanoma
  • Germ cell carcinoma,
  • Small-cell lung cancer
• Measurable disease by MRI of the brain
• Not requiring immediate surgical decompression (may qualify after surgery, if remaining measurable brain lesions)

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2 (corresponds to recursive partitioning analysis groups I or II)
• Life expectancy > 4 months
• Able to understand the aim of trial and to comply with follow-up
• No HIV seropositivity

PRIOR CONCURRENT THERAPY:

• Prior dexamethasone allowed provided it is tapered before initiation of study radiotherapy
• Not requiring cytotoxic treatment within 3 months after study radiotherapy
• At least 1 week since prior and no concurrent phenytoin